BioMedNewsBreaks – Way2Grow (‘W2G’) Biopharma Company Announces Entry into Cannabis Productivity, Plans for Psychedelic Research and Development

Way2Grow Nurseries (“Way2Grow” or “W2G”), a privately held biopharma company, today announced its entry into the productivity phase of cannabis cultivation, micropropagation and extraction. The company also announced its preparation of a Health Canada application towards psychedelic research and development for a medicinal mushroom (Psilocybe semilanceata) Dealer Licence and a Section 56 Exemption for use of psilocybin production and extraction for planned preclinical research under scientific purposes, per the Controlled Drugs and Substances Act (the “CDSA”). According to the update, W2G has secured approval for a single-story production facility designed to support tissue culture and micropropagation and to meet organic cannabis cultivation, processing and medical sales requirements. The company’s plans include expansion of its bio-pharmaceutical and bio-nutraceutical research laboratory, the addition of controlled rooms for the cultivation production, extraction and formulation of psilocybin mushrooms (Psilocybe semilanceata), as well as the addition of a medical dispensary in Osoyoos, British Columbia.

To view the full press release, visit https://ibn.fm/jKOm8

About Way2Grow Nurseries (“W2G”)

Way2Grow is a privately held biopharmaceutical company in the cannabis and psychedelic industries. W2G began with an organic vision to help patients gain better access to high quality, consistent, organic products. To achieve this vision, W2G has developed a consistent phyto-pharmaceutical feedstock growth plan through the use of tissue culture and molecular biology. These methods allow for the standardization of the procedures used to ensure quality and consistency of W2G’s biopharmaceuticals.

W2G’s extensive research and IP approach is focused on the development of several new plant-based cultivation techniques, hybrid cultivar development, genetic profiling and tissue culture. By developing a molecular breeding and genetics program, W2G can identify new bioactive compounds to determine interactions with specific genes responsible for chronic diseases.

Way2Grow is located in Osoyoos, British Columbia, and is regulated under the Cannabis Act and the Cannabis Regulations (Canada). For more information, visit the company’s website at www.W2G.ca. 

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork